Neoclease designs custom nucleases with generative AI: gene editors built for one target, miniaturized to reach tissue standard editors can't.
Finding a new nuclease used to mean searching nature for one. What if we could rewrite our genetics to eliminate the root causes of disease, rather than just treat their symptoms?
Our first editor targets LRRK2, with the goal of slowing or halting Parkinson's disease progression at its genetic root.
View the pipelineWith over 6,000 monogenic diseases in existence, we refuse to rely on a one-size-fits-all approach, instead developing tailored nucleases, each designed to combat a specific disease or gene of interest.
Our nucleases are engineered for precision editing for one specific DNA gene, aiming to reduce side effects and open the door to real cures, not just symptom management.
Meet the teamNeoclease collaborates with and is supported by research institutions and industry partners to drive innovation in gene-editing technologies and therapies, because a challenge this large can't be solved solo.
